In this regard, there is considerable value in exploring p53 pathway targets as strategic avenues to enhance tumor immunity in CLL, possibly in combination with existing immunomodulatory agents such as PD-1/PD-L1 inhibitors, lenalidomide and ibrutinib (Figure 4) [157,179,180]. The gene discussed is TP53; the disease is neoplasm.